Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

4 treatments under study, led by Metformin

Research Leaders

5 sponsors active, led by Mayo Clinic

Related Conditions

Often studied with 6 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

4Total
Not Applicable (2)
Phase 1 (1)
Phase 4 (1)

Trial Status

Unknown2
Withdrawn1
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT06337253Phase 4Unknown

Seasonal Malaria Chemoprevention Rapid Assessment Study Mozambique

NCT04266353Not ApplicableWithdrawnPrimary

Effect of Resveratrol on Serum IGF2 Among African American Women

NCT04885426Not ApplicableUnknown

Metformin for the Prevention of CRA Recurrence

NCT00955149Phase 1Completed

Erlotinib for Chemoprevention in Trisomy 7 Positive Primary Sclerosing Cholangitis (PSC)

Showing all 4 trials

Research Network

Common Treatments

  • Metformin1
  • Sulfadoxinepyrimethamine Plus Amodiaquine1
  • Resveratrol Rsv1
  • Erlotinib1

Active Sponsors

  • Mayo Clinic1
  • Genentech, Inc.1
  • Loma Linda University1
  • Jing-yuan Fang, MD, Ph. D1
  • Malaria Consortium1

Top Investigators

Related Conditions

  • Metformin1
  • Colorectal Adenoma1
  • Cholangiocarcinoma1
  • Malariafalciparum1
  • Primary Sclerosing Cholangitis1

Activity Timeline